Literature DB >> 31841631

DARK Classics in Chemical Neuroscience: Kratom.

Changho Han1, Joza Schmitt1, Kristen M Gilliland1.   

Abstract

The psychoactive plant kratom is a native plant to Southeast Asia, and its major bioactive alkaloid is mitragynine. Mitragynine exerts its analgesic properties by acting on the opioid receptors. One of its active metabolites, 7-hydroxymytraginine, is found to be 40 times more potent than mitragynine and 10 times more potent than morphine. Interestingly, current research suggests that mitragynine behaves as an atypical opioid agonist, possessing analgesic activity with less severe side effects than those of typical opioids. Although Thailand and Malaysia have criminalized the use, possession, growing, or selling of kratom due to its abuse potential, kratom still remains unregulated in the United States. The U.S. Drug Enforcement Agency (DEA) listed kratom as a "drug of concern" in 2008 with the intent to temporarily place mitragynine and 7-hydroxymitragynine onto Schedule I of the Controlled Substances Act. However, responses from the general public, U.S. Congress, and Kratom Alliances had the DEA retract their intent. Kratom is currently marketed in the United States as a dietary or herbal supplement used to treat chronic pain, anxiety, and depression with over $207 million in annual sales in the United States alone. Here, we will review the traditional and medicinal uses of kratom along with the synthesis of its bioactive ingredients and their pharmacology, metabolism, and structure-activity relationships. The importance in society of this currently controversial substance will also be discussed.

Entities:  

Keywords:  7-hydroxymitragynine; Kratom; Mitragyna speciosa; alkaloid; drug of concern; indole; mitragynine; opioid

Year:  2020        PMID: 31841631     DOI: 10.1021/acschemneuro.9b00535

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  3 in total

1.  Activity of Mitragyna speciosa ("Kratom") Alkaloids at Serotonin Receptors.

Authors:  Francisco León; Samuel Obeng; Marco Mottinelli; Yiming Chen; Tamara I King; Erin C Berthold; Shyam H Kamble; Luis F Restrepo; Avi Patel; Lea R Gamez-Jimenez; Carolina Lopera-Londoño; Takato Hiranita; Abhisheak Sharma; Aidan J Hampson; Clinton E Canal; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2021-09-01       Impact factor: 8.039

2.  Kratom pharmacology: Clues from planarians exposed to mitragynine.

Authors:  Sarah Uddin; Sonita Wiah; Tony Kim; Mia N Watson; Tyra Jennings; Scott M Rawls
Journal:  Physiol Behav       Date:  2021-06-17

Review 3.  A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.

Authors:  Elisabeth Prevete; Kim Paula Colette Kuypers; Eef Lien Theunissen; Ornella Corazza; Giuseppe Bersani; Johannes Gerardus Ramaekers
Journal:  Hum Psychopharmacol       Date:  2021-07-26       Impact factor: 2.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.